2005
Outcomes by Race and Etiology of Patients With Left Ventricular Systolic Dysfunction
Thomas KL, East MA, Velazquez EJ, Tuttle RH, Shaw LK, O’Connor C, Peterson ED. Outcomes by Race and Etiology of Patients With Left Ventricular Systolic Dysfunction. The American Journal Of Cardiology 2005, 96: 956-963. PMID: 16188524, DOI: 10.1016/j.amjcard.2005.07.002.Peer-Reviewed Original ResearchConceptsProportional hazards regression modelsLV systolic dysfunctionVentricular systolic dysfunctionSystolic dysfunctionNonischemic etiologyHeart failureAdjusted Cox proportional hazards regression modelNew York Heart Association class IICox proportional hazards regression modelRacial differencesIschemic LV systolic dysfunctionSignificant coronary artery diseaseLong-term mortality riskWorse long-term outcomesNonischemic LV dysfunctionOutcomes of patientsSystolic heart failureEtiology of patientsLV ejection fractionCoronary artery diseaseLong-term outcomesHazards regression modelsLV dysfunctionWorse survivalArtery disease
2004
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal 2004, 148: 122-128. PMID: 15215801, DOI: 10.1016/j.ahj.2003.12.040.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCost-Benefit AnalysisDrug Therapy, CombinationFemaleFollow-Up StudiesHealth Care CostsHealth ResourcesHeart FailureHospitalizationHumansMaleMiddle AgedOutcome Assessment, Health CareProportional Hazards ModelsRandomized Controlled Trials as TopicTetrazolesValineValsartanConceptsValsartan Heart Failure TrialHeart failure hospitalizationHeart Failure TrialHeart failureACE inhibitorsFailure hospitalizationFailure TrialNew York Heart Association class IIIncremental costChronic heart failureMean incremental costOutpatient physician servicesBackground therapyCardiovascular medicationsNet incremental costClinical benefitPrescribed therapyClinical signsAmbulance transportationPatientsUnit cost estimatesHealth outcomesPlaceboValsartanClass II
2002
Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank)
O’Connor C, Velazquez EJ, Gardner LH, Smith PK, Newman MF, Landolfo KP, Lee KL, Califf RM, Jones RH. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). The American Journal Of Cardiology 2002, 90: 101-107. PMID: 12106836, DOI: 10.1016/s0002-9149(02)02429-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac CatheterizationComorbidityCoronary AngiographyCoronary Artery BypassCoronary Artery DiseaseDisease-Free SurvivalFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedOutcome and Process Assessment, Health CareSurvival AnalysisTimeTreatment OutcomeVentricular Dysfunction, LeftConceptsCoronary artery bypass surgeryLong-term outcomesMedical therapyCoronary diseaseIschemic cardiomyopathyNew York Heart Association class IILeft ventricular ejection fractionCox proportional hazards modelDuke University Medical CenterDays of catheterizationInitial cardiac catheterizationMedical therapy armObservational treatment comparisonsCoronary artery bypassHeart failure symptomsMedical therapy groupVentricular systolic dysfunctionArtery bypass surgeryVentricular ejection fractionCoronary artery diseaseEpicardial coronary vesselsProportional hazards modelUniversity Medical CenterCABG groupTherapy arm